Breast CancerNCT07392424
BreastCancerPEP: A Six-Month Online Empowerment Program to Improve Mental and Physical Health in Women With Breast Cancer
A study testing Breast Cancer Patient Empowerment Program (BreastCancerPEP) in people with Breast Cancer, run by Gabriela Ilie at 1 site in Canada.
Trial summary
This study is evaluating a six-month, home-based Patient Empowerment Program (Breast Cancer PEP) for women receiving treatment for newly diagnosed invasive breast cancer. The program provides daily guidance on physical activity, arm and shoulder rehabilitation, stress-reduction practices, healthy lifestyle habits, and… Read more about this study
- Who is it for?
- Ages 19 years and older, women only
- Conditions the study is for
- Breast Cancer
- What is being tested?
- Breast Cancer Patient Empowerment Program (BreastCancerPEP)
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 160 participants
- Where
- 1 siteCanada
- Study dates
- 15 Mar 2026to 15 Mar 2029
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants must meet all of the following criteria:
- Age ≥ 18 years.
- Diagnosis: Biopsy-confirmed invasive breast cancer.
- Treatment Plan: Scheduled to undergo breast cancer surgery, with or without neoadjuvant chemotherapy.
- Medical Safety for Exercise: Able to safely participate in low-to-moderate physical activity and light resistance training based on study screening. Participants with a history of myocardial infarction, stroke, or other significant cardiovascular conditions within the last 12 months require documented medical clearance from a Family Physician, Oncologist, or Cardiologist.
- Residence: Resides in Nova Scotia and able to participate in a province-wide, digitally delivered program.
Show all 9Show fewer
- Digital Access and Literacy: Regular access to email and the internet on a computer, tablet, or smart phone. Able to open emailed links and navigate online videos and surveys (caregiver assistance permitted). Has an active email account or willingness to create one and check it daily.
- Language Ability: Able to read, speak, and understand English sufficiently to follow program content and complete study questionnaires.
- Study Participation Requirements: Willing and able to complete online questionnaires at baseline, 6 months, and 12 months. Willing to complete weekly self-reported compliance surveys during the 6-month intervention period.
Who cannot join
- Participants will be excluded if any of the following apply:
- Medical Contraindications: Myocardial infarction, stroke, or other major cardiovascular event within the past 12 months without medical clearance indicating safety for exercise. Any medical, orthopedic, neurological, or other condition that would preclude safe participation in a home-based physical activity program.
- Digital Access Limitations: Inability to access the internet or lack of a device necessary to receive daily emails or view program videos. Inability to navigate online videos or survey links, even with caregiver assistance.
- Participation Limitations: Unwillingness or inability to complete required questionnaires or engage with digitally delivered program components.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site
Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, B3H 1V7
Gabriela Ilie, PhD, 902-989-4114, Gabriela.Ilie@dal.ca
About this study
Official title: BreastCancerPEP: A Randomized Trial of a Six-Month Online Empowerment Program to Improve Mental and Physical Health in Women With Breast Cancer
This study is evaluating a six-month, home-based Patient Empowerment Program (Breast Cancer PEP) for women receiving treatment for newly diagnosed invasive breast cancer. The program provides daily guidance on physical activity, arm and shoulder rehabilitation, stress-reduction practices, healthy lifestyle habits, and social support, all delivered through online videos, emails, and optional group sessions.
The purpose of the study is to learn whether this program can reduce psychological distress and improve overall well-being compared with standard cancer care. Psychological distress will be measured using a simple questionnaire called the Kessler Psychological Distress Scale (K10). The study will also look at general health, quality of life, and participants' experiences with the program.
Read more
A total of 160 women across Nova Scotia will take part. Participants will be randomly assigned to start the program right away or to receive standard care for six months before getting access to the program. Everyone will complete online questionnaires at the beginning of the study and again at 6 and 12 months. A small number of participants may also be invited to take part in optional interviews to share their experiences.
Researchers will also explore how participants use the digital program, what parts are most helpful, and whether the program could be offered more broadly in the future. The trial is being conducted across all Nova Scotia Health zones and coordinated through the QEII Health Sciences Centre.
Read the detailed description
Breast Cancer PEP (BC-PEP) is a six-month, home-based, digitally delivered supportive-care program designed for individuals undergoing treatment for newly diagnosed invasive breast cancer. The program integrates physical activity, upper-limb rehabilitation, mindfulness, nutrition education, and self-management strategies. BC-PEP is based on prior PEP programs evaluated in Atlantic Canada, which demonstrated high feasibility and strong participant engagement.
In this randomized, wait-list-controlled trial, participants assigned to the early-intervention arm begin the 6-month BC-PEP program immediately after randomization, while participants in the wait-list control arm receive standard care for 6 months before initiating the same program. All participants are followed for approximately 12 months to assess intervention effects and longer-term outcomes. Randomization and allocation procedures are conducted centrally, and the study is implemented across multiple Nova Scotia Health sites.
Intervention Delivery:
BC-PEP is delivered primarily through automated daily emails generated via REDCap over 182 consecutive days. Each email provides a structured set of activities, including:
Progressive aerobic activity designed to meet oncology-specific guidelines Twice-weekly resistance-training sessions using household equipment or elastic bands Daily stretching and upper-limb rehabilitation exercises aligned with surgical recovery timelines A 10-minute daily mindfulness or relaxation practice Short educational modules addressing sleep, stress coping, communication, body image, and nutrition
Participants have access to a video library with instructional content, may engage in an optional peer-support "buddy system," and are invited to monthly videoconference sessions with study clinicians.
Implementation and Engagement Monitoring Engagement metrics are collected throughout the program, including weekly adherence surveys, email-open rates, video-view data, and participation in monthly sessions. Implementation outcomes will be examined using a Hybrid Type I effectiveness-implementation approach guided by the RE-AIM framework.
This digital, low-cost program is designed to be scalable and accessible across diverse geographic regions. Study findings are intended to inform the effectiveness and implementation potential of BC-PEP as part of routine supportive cancer care.
- Conditions
- Breast Cancer
- Being tested
- Breast Cancer Patient Empowerment Program (BreastCancerPEP)
- Keywords
- empowerment, mental health, patient activation, health promotion, breast cancer, quality of life, psychological distress, digital health, self-management, patient-reported outcomes, patient-centred care, lifestyle intervention, cancer survivorship
- Medical subject headings
- Breast Neoplasms, Empowerment, Psychological Well-Being, Patient Participation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Breast Cancer Patient Empowerment Program (BreastCancerPEP)Behavioural
The Breast Cancer Patient Empowerment Program (Breast Cancer PEP) is a 6-month, home-based digital behavioural intervention delivered through daily automated emails containing structured physical activity guidance, resistance-band and body-weight strength training, yoga and stretching routines, arm and shoulder rehabilitation exercises, mindfulness and relaxation practices, and lifestyle education modules. Optional peer-support check-ins and monthly videoconference group sessions are included. Intervention content is standardized through a 182-day pre-programmed email and video library. Participants in both study arms receive the same intervention content, with timing dependent on randomization assignment.
| Study group | Role | What they receive |
|---|---|---|
| Early Intervention (Experimental) | Experimental | Participants randomized to the Early Intervention arm will begin the Breast Cancer Patient Empowerment Program (Breast Cancer PEP) immediately after baseline assessment. The 6-month, home-based digital program includes daily emails with structured physical activity guidance, arm and shoulder rehabilitation exercises, mindfulness practices, and lifestyle education modules, along with optional peer-support check-ins and monthly videoconference sessions. Participants complete weekly self-report compliance surveys throughout the 6-month program. Receives: Behavioral: Breast Cancer Patient Empowerment Program (BreastCancerPEP) |
| Delayed Intervention / Wait-List Control (Active Comparator) | Active comparator | Participants randomized to the Delayed Intervention arm receive usual care for the first 6 months following baseline assessment. No program materials or intervention content are provided during this period. At approximately 6 months, participants complete follow-up assessments and then begin the same 6-month Breast Cancer Patient Empowerment Program (Breast Cancer PEP) as the Early Intervention arm, including daily digital content, rehabilitation exercises, mindfulness practices, lifestyle modules, optional peer-support, and monthly videoconference sessions. Receives: Behavioral: Breast Cancer Patient Empowerment Program (BreastCancerPEP) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of participants with clinically significant psychological distress (Kessler Psychological Distress Scale-10 ≥20)
Proportion of participants scoring ≥20 on the Kessler Psychological Distress Scale-10 (K10) at 6 months after randomization. The K10 is a validated 10-item measure of psychological distress with scores ranging from 10-50, where higher scores indicate worse distress.
Measured: 6 months after randomization (Day 183 ± 2 days)
Secondary outcomes (18)
Change in psychological distress (Kessler Psychological Distress Scale-10 total score)
Change in total score on the Kessler Psychological Distress Scale-10 (K10) from baseline to 6 and 12 months. The K10 ranges from 10-50, with higher scores indicating worse distress. This outcome complements the primary binary measure by assessing psychological distress as a continuous variable.
Measured: Baseline to 6 months; baseline to 12 months
Change in health-related quality of life (SF-12v2 Physical and Mental Component Scores)
Change in SF-12v2 Physical Component Summary (PCS) and Mental Component Summary (MCS) scores from baseline to 6 and 12 months. Scores range from 0-100, with higher scores indicating better health status.
Measured: Baseline to 6 months; baseline to 12 months
Change in health utility score (SF-6D)
Change in SF-6D health utility score derived from SF-12v2 responses. Scores range from approximately 0.29-1.00, with higher scores indicating better health-related quality of life.
Measured: Baseline to 6 months; baseline to 12 months
Change in cancer-specific quality of life (EORTC QLQ-C30)
Change in EORTC QLQ-C30 domain scores. All scales transformed to 0-100. Higher scores indicate better functioning for functional scales and worse symptoms for symptom scales; higher global health = better QoL.
Measured: Baseline to 6 months; Baseline to 12 months.
Change in breast cancer-specific quality of life (EORTC QLQ-BR23)
Change in QLQ-BR23 domain scores (0-100). Higher functional scores indicate better functioning; higher symptom scores indicate worse symptoms.
Measured: Baseline to 6 months; Baseline to 12 months.
Change in self-efficacy (Self-Efficacy for Managing Chronic Disease 6-item Scale)
Change in SEMCD-6 total score. Scores range 1-10; higher scores indicate greater self-efficacy.
Measured: Baseline to 6 months; baseline to 12 months
Change in patient activation (Patient Activation Measure-13)
Change in PAM-13 total score. Scores range 0-100; higher scores indicate greater activation.
Measured: Baseline to 6 months; baseline to 12 months
Change in generalized anxiety symptoms (GAD-7)
Change in GAD-7 total score. Scores range 0-21; higher scores indicate greater anxiety.
Time Frame: Baseline to 6 months; Baseline to 12 months.
Measured: Baseline to 6 months; baseline to 12 months
Change in cognitive function (PROMIS® Short Form v2.0 - Cognitive Function 8a)
Change in PROMIS Cognitive Function 8a T-score. T-scores typically range ~20-80; higher T-scores indicate better cognitive function.
Measured: Baseline to 6 months; baseline to 12 months
Change in upper-limb disability and symptoms (QuickDASH)
Change in QuickDASH total score. Scores range 0-100; higher scores indicate greater disability/symptoms (worse function).
Measured: Baseline to 6 months; baseline to 12 months
Change in menopause symptoms (Menopause Quick 6)
Change in MQ-6 total score (6 items; scale scoring varies by version). Higher scores indicate more severe menopause symptoms.
Measured: Baseline to 6 months; baseline to 12 months
Change in social support (Medical Outcomes Study Social Support Survey)
Change in MOS-SSS summary score (and/or subscales). Scores transformed to 0-100; higher scores indicate greater perceived social support.
Measured: Baseline to 6 months; baseline to 12 months
Change in body weight (self-reported kilograms)
Change in participant self-reported body weight (kg) from baseline to 6 and 12 months.
Measured: Baseline to 6 months; baseline to 12 months
Change in diet quality (Rapid Eating Assessment for Participants - Shortened v2)
Change in REAP-S v2 total score. Scores range from 0-60; higher scores indicate healthier dietary habits.
Measured: Baseline to 6 months; baseline to 12 months
Self-reported adherence to cancer treatment
Proportion of participants reporting full adherence to prescribed cancer treatment(s) via questionnaire.
Measured: Baseline to 6 months; baseline to 12 months
Clinically verified adherence to cancer treatment
Proportion of participants documented as adherent in medical records.
Measured: Baseline to 6 months; baseline to 12 months
Number of hospitalizations (administrative data)
Count of all-cause hospitalizations per participant from linked administrative data.
Measured: Baseline to 6 months; baseline to 12 months
Number of physician billing events (administrative data)
Count of physician billing events per participant from linked provincial administrative databases.
Measured: Baseline to 6 months; baseline to 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Feb 2026
- Study start15 Mar 2026 (estimated)
- Primary completion15 Mar 2028 (estimated)
- Study completion15 Mar 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 160 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Gabriela Ilie
- Sponsor type
- University, hospital or other
- Collaborators
- Nova Scotia Health Authority, Dalhousie University, Queen Elizabeth II Health Sciences Centre
- Responsible party
- Sponsor-investigator, Gabriela Ilie, Nova Scotia Health Authority
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07392424
- Sponsor's protocol ID
- BreastCancerPEP-RCT-2026
- Status last verified
- Jan 2026
- First submitted
- 21 Nov 2025
- Last updated
- 6 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No